Apollomics (APLM) News Today → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free APLM Stock Alerts $0.41 +0.01 (+1.86%) (As of 05:26 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Geneglobenewswire.com - April 25 at 8:30 AMApollomics (APLM) Price Target Decreased by 58.93% to 5.87msn.com - April 17 at 4:58 PMApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo Financefinance.yahoo.com - April 16 at 7:35 AMApollomics, Inc. (NASDAQ:APLM) Sees Large Increase in Short Interestmarketbeat.com - April 10 at 10:24 AMApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meetingglobenewswire.com - April 10 at 7:00 AMQ1 2024 EPS Estimates for Apollomics, Inc. Decreased by Analyst (NASDAQ:APLM)marketbeat.com - April 3 at 6:00 AMApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meetingfinance.yahoo.com - April 2 at 3:17 PMHC Wainwright Trims Apollomics (NASDAQ:APLM) Target Price to $5.00marketbeat.com - April 1 at 8:30 AMApollomics GAAP EPS of -$2.32msn.com - March 28 at 11:21 AMApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 7:00 AMApollomics (APLM) Set to Announce Quarterly Earnings on Thursdaymarketbeat.com - March 27 at 9:30 AMApollomics Names Matthew Plunkett as Chief Financial Officerfinance.yahoo.com - March 4 at 1:54 PMApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officerglobenewswire.com - March 4 at 7:00 AMApollomics Stock (NASDAQ:APLM), Short Interest Reportbenzinga.com - February 22 at 10:22 PMShort Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 54.5%marketbeat.com - February 12 at 2:57 PMApollomics (NASDAQ:APLM) Stock Price Down 1.2%marketbeat.com - February 3 at 2:53 AMApollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyfinanznachrichten.de - January 20 at 10:31 AMApollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyfinance.yahoo.com - January 19 at 6:24 PMApollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conferencestockhouse.com - January 17 at 10:20 PMApollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatmentfinance.yahoo.com - January 3 at 8:16 PMApollomics Inc Ordinary Shares - Class A APLMmorningstar.com - December 17 at 8:10 AMApollomics Inc Ordinary Shares - Class Amorningstar.com - December 12 at 10:58 PMApollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medicationfinance.yahoo.com - December 7 at 2:51 PMApollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutationfinance.yahoo.com - December 4 at 7:41 AMApollomics, Inc. (APLM)ca.finance.yahoo.com - November 28 at 8:30 AMApollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)finance.yahoo.com - November 28 at 8:30 AMApollomics Shares More Than Double on Partner's Approval for Commercialization of Vebreltinibmarketwatch.com - November 16 at 1:37 PMWhy Is Cancer Firm Apollomics Stock Trading Higher Today?msn.com - November 16 at 1:37 PMApollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancerfinance.yahoo.com - November 16 at 8:37 AMApollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulationfinance.yahoo.com - October 31 at 9:09 AMApollomics stock soars 76% following positive report for brain cancer therapymsn.com - October 27 at 5:23 PMWhat's Going On With Apollomics Inc Stock?benzinga.com - October 27 at 12:23 PMmarketbeat.com - October 27 at 9:41 AMWhy Is Apollomics (APLM) Stock Up 113% Today?investorplace.com - October 27 at 9:12 AMApollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusionfinance.yahoo.com - October 26 at 10:37 AMAnalysts Offer Insights on Financial Companies: W. R. Berkley Corporation (WRB), Apollomics (APLM) and Northwest Bancshares (NWBI)markets.businessinsider.com - October 24 at 8:40 PMApollomics Treating MET-Altered Cancers: KUNPENG Trial Resultsfinance.yahoo.com - October 24 at 10:39 AMApollomics stock rallies 35% pre-market on encouraging lung cancer studymsn.com - October 23 at 9:38 AMApollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%finance.yahoo.com - October 23 at 9:38 AMApollomics Announces Presentations of Vebreltinib Data at ESMO 2023finance.yahoo.com - October 16 at 10:19 PMBuy Rating on Apollomics Based on Promising Future Prospects and High Potential of Vebreltinib in Cancer Treatmentmarkets.businessinsider.com - October 3 at 7:58 AMApollomics Reports First Half 2023 Financial Results and Provides Corporate Updatetmcnet.com - September 28 at 8:16 PMApollomics, Inc. (NASDAQ:APLM) Sees Large Growth in Short Interestmarketbeat.com - September 15 at 11:00 AMAPLM - Apollomics, Inc.finance.yahoo.com - July 30 at 5:40 PMRetail investors account for 44% of Apollomics, Inc.'s (NASDAQ:APLM) ownership, while private equity firms account for 21%finance.yahoo.com - July 20 at 7:49 AMApollomics (NASDAQ: APLM)fool.com - July 8 at 3:18 PMQiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaqfinance.yahoo.com - June 19 at 3:09 PMApollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposiumfinance.yahoo.com - June 19 at 3:09 PMQ1 2023 Earnings Forecast for Apollomics, Inc. Issued By HC Wainwright (NASDAQ:APLM)marketbeat.com - June 5 at 1:28 AMmarketbeat.com - April 11 at 9:58 AM Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results. Don't miss out on the "next Ozempic" >>> APLM Media Mentions By Week APLM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLM News Sentiment▼0.000.37▲Average Medical News Sentiment APLM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLM Articles This Week▼11▲APLM Articles Average Week Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ProMIS Neurosciences News Today Xilio Therapeutics News Today Unicycive Therapeutics News Today Lexaria Bioscience News Today Marker Therapeutics News Today Eyenovia News Today VYNE Therapeutics News Today Acurx Pharmaceuticals News Today Cara Therapeutics News Today BriaCell Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLM) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
